Eli Lilly expands long-acting Cardiometabolic Partnership With Camurus

Camurus (NASDAQ:CAMX) announced Monday that Eli Lilly (NYSE:LLY) has formally exercised its option to integrate amylin receptor agonists into the companies' existing cardiometabolic collaboration and license agreement.

The strategic decision extends Lilly's exclusive, global rights to deploy Camurus' proprietary FluidCrystal injection technology to an additional class of long-acting therapeutics.

The expanded framework now encompasses up to four proprietary Lilly drug compounds stretching across three distinct therapeutic classes: dual GLP-1 and GIP receptor agonists; triple agonists for GLP-1, GIP, and glucagon receptor agonists; and the newly added amylin receptor agonists.

The technology is engineered to enable the extended release of peptide-based medicines, shifting dosing schedules from daily or weekly configurations to long-acting subcutaneous depots that maintain steady drug release over weeks or months via prefilled syringes or autoinjector pens.

The exercise of the amylin option triggers an immediate $5 million payment to Camurus.

Under the consolidated terms of the broader collaboration, which originally launched in June 2025, the Sweden-based biotech remains eligible to secure up to $290 million in upfront development and regulatory milestone payments.

Furthermore, the commercial contract outlines up to $580 million in potential sales-based milestones.

In the event that these clinical candidates achieve regulatory clearance and market commercialization, Lilly will also pay Camurus tiered, mid-single-digit royalties based on global net product sales.